67%) was the commonest cause of the liver disease
followed by glycogen storage disease (11, 7.
is responsible for almost 12% of deaths in men aged 40 to 49 years and is now the fourth most common cause of years of life lost in people aged under 75, after heart disease and lung cancer.
There are more than 100 types of liver disease
and while official figures suggest one in five people are at risk of liver damage, Langford believes the true figure is nearer to one in three.
The report shows that there has been a 7% reduction in the number of people dying from alcohol-related liver disease
in the past five years, from 494 deaths in 2010 to 459 deaths in 2014.
is the 12th most common cause of death in the USA and the prevalence of liver diseases
such as NASH, liver cancer and Hepatitis C are on the rise with almost 10% of the US population having some form of liver disease
It's absolutely wonderful that this research is going to help not just me, but lots of other people with nonalcoholic fatty liver disease
, and I'm all for studies that gain a better understanding into this disease.
Intense Interest in Drug Therapies for Liver Disease
Conclusions: In chronic liver disease
protein C may be useful for assessment of hepatocellular damage in cirrhosis.
The sensitivity of serum cholinesterase to diagnose liver disease
Every contribution, however small, helps to make a real difference to the lives of families affected by liver disease
Responding a query about the survival period of liver disease
patient, he said it varies with respect to its intensity and stages of disease, however, a liver disease
patient may expire within one to six years if not treated properly.
Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease
with advanced fibrosis.
USPRwire, Wed Aug 28 2013] Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease
(NAFLD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline.
M2 EQUITYBITES-August 13, 2013-Galectin Therapeutics awarded FDA fast track designation for GR-MD-02 for fatty liver disease
, NASH(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-August 13, 2013-Galectin Therapeutics awarded FDA fast track designation for GR-MD-02 for fatty liver disease
, NASH(C)2013 M2 COMMUNICATIONS